U.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device Designation for its EsoGuard Esophageal DNA Test
February 11, 2020 09:30 ET
|
PAVmed Inc.
NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...
PAVmed Reports Third Quarter 2019 Financial Results and Provides Business Update
November 21, 2019 16:00 ET
|
PAVmed Inc.
Conference call to be held on November 21, 2019 at 4:30 p.m. Eastern time NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly...
PAVmed Partners with Laser Technology Pioneer Dr. Jacob Wong to Develop and Commercialize Non-Invasive Laser-based Diagnostic Products
November 14, 2019 09:30 ET
|
PAVmed Inc.
Secures exclusive worldwide license for Nondispersive Infrared (NDIR) laser technology Launches joint development program for NDIR laser-based diagnostic products to measure glucose, electrolytes...
USPTO Grants PAVmed Patent Covering its CarpX™ Device
August 21, 2019 09:30 ET
|
PAVmed Inc.
NEW YORK, Aug. 21, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the U.S....
PAVmed Announces PortIO™ Breakthrough
March 13, 2019 08:04 ET
|
PAVmed Inc.
Groundbreaking implantable intraosseous vascular access device achieves unprecedented maintenance-free implant duration of over 60 days in pre-clinical testing NEW YORK, March 13, 2019 (GLOBE...
PAVmed Provides Business Update
July 25, 2018 07:30 ET
|
PAVmed Inc.
FDA confirms receipt of CarpX 510(k) resubmission for review NEW YORK, July 25, 2018 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated,...